AI assistant
Syncom Formulations (India) Ltd. Interim / Quarterly Report 2026
60987_rns_2025-08-08_f1e2486e-716e-4038-a197-f81158f88f56.pdf
Interim / Quarterly Report
Open in viewerOpens in your device viewer
SYNCOM/SE/2025-26 08th August, 2025
Online filing at: www.listing.bseindia.com and https://neaps.nseindia.com/NEWLISTINGCORP/login.jsp
To, BSE Limited Phiroze Jeejeebhoy Tower, Dalal Street, Mumbai (M.H.) 400 001 BSE CODE:524470
To, National Stock Exchange of India Limited Exchange Plaza, C-1, Block G, Bandra Kurla Complex, Bandra (E), Mumbai- 400051 NSE SYMBOL: SYNCOMF
Subject: Regulation 33(3) of SEBI (LODR) Regulations, 2015- Submission of the Un-Audited Standalone and Consolidated Financial Results along with Limited Review Report thereon for the Quarter ended 30th June, 2025.
Dear Sir/Ma'am,
This is in continuation of our letter no. SYNCOM/SE/2025-26 dated 2 nd August, 2025 regarding intimation of Board meeting for consideration and approval of Quarterly Un-Audited Standalone and Consolidated Financial Results for the quarter ended 30th June, 2025.
Pursuant to Regulation 33(3) of SEBI (LODR) Regulations, 2015, we are pleased to submit the Un-Audited Standalone and Consolidated Financial Results along with Limited Review Report thereon for the Quarter ended 30th June, 2025, in PDF Format, which were also approved and recommended by the Audit Committee and further approved by the Board of Directors at their meeting held on Friday, 08th August 2025.
The Board Meeting was commenced at 4:00 P.M. and concluded at 04:45 P.M.
The Financial Results will also be published in widely circulated English & Marathi (Vernacular) newspaper in the prescribed format within the stipulated time period.
We are also in process to file the aforesaid financial results in XBRL format within the stipulated time and same shall also be hosted at the website of the company.
You are requested to take on record the above said Un-Audited Standalone and Consolidated Financial Results along with Limited Review Report for your reference and record.
Thanking You Yours Faithfully For, SYNCOM FORMULATIONS (INDIA) LIMITED
Vaishali Agrawal Digitally signed by Vaishali Agrawal Date: 2025.08.08 16:49:59 +05'30'
CS VAISHALI AGRAWAL COMPANY SECRETARY & COMPLIANCE OFFICER Encl: Unaudited Standalone and Consolidated Financial Results and Limited Review Report.
SYNCOM FORMULATIONS (rNDrA) L|MTTED
Regd Off - /,Niraj lndustrial F state,Off Mahakali Caves Road,Andheri (E) Mumbai-400093
Works:- 256-257, Sector - 1, Pithampur, Dist: Dhar-454775
E Mail:- [email protected], Website:- www.sfil.in, CIN :- L24239MH1988PLC047759
STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 3OTH JUNE, 2025
| (Rs.ln Lakhs) ( Except EPS) | |||||
|---|---|---|---|---|---|
| S. No. |
Pa rtic u la rs | Quarter Ended | Year Ended | ||
| 30t06t2025 | 3110312025 | 30t06t2024 | 31t03t202s | ||
| U naud ited | Audited* | Unaudited | Audited | ||
| 1 | Revenue from Operations | 1 1654.69 | 14846 33 | 8683 09 | 46284 93 |
| 2 | Other lncome | 601 97 | 690.31 | 131.31 | 1719 12 |
| 3 | Total lncome (1+ 2l | 12256.66 | 15536.64 | 8814.40 | 48004.05 |
| 4 | EXPENSES | ||||
| ( a ) Cost of materials consumed | 5961 30 | 8016 05 | 5303 1 3 | 2780? 93 | |
| ( b ) F)urchases of Stock-in- l'radc (c )Changes in rnventories of finished goods, Stock-in- Trade |
1 56'l 93 | 1 568 48 | 406 08 | 394'i / 1 | |
| and work-in-progress | (616 3e) | 438 80 | (263 2e) | (1062 24) | |
| ( d ) Employee benefits expense | 1595 44 | 1497.47 | 964.92 | 521'/ 37 | |
| (e ) [iinance costs | 23 74 | 8.92 | 38 65 | 85 02 | |
| ( f ) Depreciation and amortization expense | 134.00 | 128.64 | 130 00 | 519 39 | |
| (g)Otherexpenses | 1574 94 | 1578 33 | 1225 22 | 5028 63 | |
| Total expenses(4) | 10234.96 | 13236.69 | 7804.71 | 41538.81 | |
| 5 | ProfiU(loss) before exceptional items and tax (3- 4) | 2021.70 | 2299.95 | 1009.69 | 6465.24 |
| 6 | Exceptional ltems | 413 | 082 | 000 | 058 |
| 7 | ProfiU(loss) before tax ( 5 - 6 ) | 2025.83 | 2300.77 | 1009.69 | 646s.82 |
| 8 | Tax expense: | ||||
| (1) Current tax | 431.60 | 450.12 | 243 77 | 1445 26 | |
| 9 | (2) Deferred tax Profit (Loss) for the period from continuing operations (7 |
21 30 | 100 45 | 306 | 133 38 |
| 8) | 1572.93 | 17 50.20 | 762.86 | 4887 ,18 | |
| 10 | Profit/(loss) from discontinued operations | 000 | 000 | 000 | 000 |
| 11 | Iax expensc of discontrnued operations | 000 | 000 | 000 | 000 |
| 12 | [)rofit/1loss) from I)rscontinued opcrations (after tax) (101 1 ) | 000 | 000 | 000 | 000 |
| 13 | ProfiU(!oss) for the period ( 9 + 12 ) | 1572.93 | 17 50.20 | 762.86 | 4887.1 I |
| 14 | Other Comprehensive lncome | ||||
| A(i )ltems that will not be reclassified to profit or loss | 000 | 0.00 | 000 | 000 | |
| (ii) lncome tax relating to items that will not be reclassified to | |||||
| profit or loss B (i ) ltems that will be reclassified to profit or loss |
000 | 000 | 000 | 000 | |
| (ii ) lncome tax relating to items that will be reclassified to profit | 403 84 | (228 1e) | 275 93 | 458 02 | |
| or loss | 000 | 0.00 | 0.00 | 000 | |
| 15 | Tota! Comprehensive lncome for the period (Xlll+XlV) | ||||
| (Comprising Profit (Loss) and Other Comprehensive lncome for the period) |
1976.77 | 1522.01 | 1038.79 | 5345.20 | |
| 16 | Paid up Share Capital of the Company (Face Value 1/-) | 9400.00 | 9400.00 | 9400 00 | 9400 00 |
| 1/ | Reserves excluding revaluation reserves | 000 | 000 | 24590 38 | |
| 18 | Earnings per equity share (for continuing operatron) | ||||
| (1) l.3asic | 0 21 | 0 16 | 0 1'1 | 0 5/ | |
| (2) Diluted | 0?1 | 016 | 011 | 0 5'/ | |
| 19 | Earnings per equity share (for discontrnued opcratron) | ||||
| (1) l3asrc | 000 | 0,00 | 000 | 000 | |
| (2) Diluted | 000 | 000 | 000 | 000 | |
| 20 | Earnings per equity share (for discontinued & continuing operations) |
||||
| (1) Basic | 021 | 016 | 011 | 057 | |
| (2) Diluted | 0 ?.1 | 016 | 011 | 0 5/ |
Place: lndore Date: 08/08/2025
ormulations (lndia) Limited
SYNCOM FORMULATIONS (INDIA) LIMITED
Regd.Off: - 7, Niraj Industrial Estate, Off Mahakali Caves Road, Andheri (E) Mumbai-400093
Works:- 256-257, Sector - 1, Pithampur, Dist: Dhar-454775
E Mail:- [email protected], Website:- www.sfil.in, CIN :- L24239MH1988PLC047759
STANDALONE STATEMENT OF SEGMENT WISE REVENUE, RESULTS ALONG WITH QUARTERLY RESULTS FOR THE QUARTER ENDED 30TH JUNE 25
| (Rs.In Lakhs) (Except EPS) | |||||
|---|---|---|---|---|---|
| Quarter Ended | Year Ended | ||||
| S. No. | Particulars | 30/06/2025 | 31/03/2025 | 30/06/2024 | 31/03/2025 |
| Unaudited | Audited* | Unaudited | Audited | ||
| $\mathbf{1}$ | Segment Revenue | ||||
| a) Pharmaceuticals Drugs & Formulations | 12,062.52 | 15,214.89 | 8585.33 | 46,784.92 | |
| b) Trading of Commodities | 104.56 | 213.45 | 132.41 | 825.84 | |
| c) Renting of Property | 89.58 | 108.30 | 96.66 | 393.29 | |
| Total Segment Revenue | 12,256.66 | 15,536.64 | 8814.40 | 48,004.05 | |
| Less: Inter Segment Revenue | 0.00 | ||||
| Revenue from Operations | 12,256.66 | 15,536.64 | 8814.40 | 48,004.05 | |
| $\overline{2}$ | Segment Results Profit(+)/Loss(-) before tax | ||||
| and interest from each segment | |||||
| a) Pharmaceuticals Drugs & Formulations | 1,960.52 | 2,205.69 | 955.36 | 6,169.90 | |
| b) Trading of Commodities | 1.35 | 4.19 | 4.39 | 20.35 | |
| c) Renting of Property | 83.57 | 99.81 | 88.59 | 360.59 | |
| Total Profit before tax | 2,045.44 | 2,309.69 | 1048.34 | 6,550.84 | |
| Less: i) Interest | 23.74 | 8.92 | 38.65 | 85.02 | |
| ii) Other Un-allocable Expenditure | 0.00 | ||||
| Profit before tax | 2,021.70 | 2,300.77 | 1009.69 | 6,465.82 | |
| $\mathbf{3}$ | (Segment Asset-Segment Liabilities) | ||||
| Segment Asset | |||||
| a) Pharmaceuticals Drugs & Formulations | 39,302.09 | 35,752.01 | 29437.25 | 35,752.01 | |
| b) Trading of Commodities | 259.18 | 448.67 | 964.42 | 448.67 | |
| c) Renting of Property | 4,733.44 | 4,767.98 | 4733.45 | 4,767.98 | |
| Total Segment Asset | 44,294.71 | 40,968.66 | 35135.12 | 40,968.66 | |
| Un-allocable Assets | 0.00 | ||||
| Net Segment Asset | 44,294.71 | 40,968.66 | 35135.12 | 40,968.66 | |
| Segment Liabilities | |||||
| a) Pharmaceuticals Drugs & Formulations | 8,185.83 | 6,754.47 | 5050.13 | 6,754.47 | |
| b) Trading of Commodities | 8.36 | 82.76 | 167.45 | 82.76 | |
| c) Renting of Property | 133.36 | 141.04 | 181.32 | 141.04 | |
| Total Segment Liabilities | 8,327.55 | 6,978.27 | 5398.90 | 6,978.27 | |
| Un-allocable Liabilities | 0.00 | ||||
| Net Segment Liabilities | 8,327.55 | 6,978.27 | 5398.90 | 6,978.27 | |
Notes:-
1 The above results were reviewed by the Audit Committee and approved by the Board at its meeting held on 08/08/2025
2 These above results have been prepared in compliance with the Indian Accounting Standard (referred to as "Ind AS") as notified prescribed under Section 133 of the Companies Act, 2013 read with Companies (Indian Accounting Standards) Rules 2015 as amended from time to time.
3 The company is operating in 3 segments i.e. (a) Pharmaceuticals Drugs & Formulations (b) Trading of Commodities (c) Renting of Property, particulars of segment wise results are given as required.
4 As required under Regulation 33 of SEBI (LODR) Regulations, 2015 the limited review by the Statutory Auditors have been completed for the quarter ended on 30th June, 2025. The report does not have any impact on the above results and notes which needs explanation.
5 Previous period figures have been regrouped/reclassified wherever necessary to confirm to this period classification.
Place: Indore Date: 08/08/2025
SANJAY MEHTA & ASSOCIATES
Ch artered Accountants
Limited Review Report on Un-audited Standalone Financial Results for the Quarter & Three Months ended 30'h June,2025 pursuant to Regulation 33 of the SEBI (LODR) Regulations,20ts
To,
Place: lndore
Date: 8'h August, 2025
The Board of Directors SYNCOM FORMULATIONS (INDIA) LIMITED Indore (M.P.)
We have reviewed the accompanying statement of Standalone Unaudited Financial Results of SyNCOM FORIVIULATIONS (INDIA) LIMITED ("the Company"), for the period ended June, 30, 2025 ('lhe Statement"), attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (LODR) Regulations, 2015, as amended including relevant circular issued by the SEBI from time to time.
This statement which is the responsibility of the Cornpany's Management and has been approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 Interim Financial Reporting" ("IND AS 34"), prescribed under Section 133 ofthe Companies Act,20l3,and other Accounting principles generally accepted in India and in compliance with the Regulation 33 of the SEBI (LODR) Regulations,2bl5, as amen-ded, including relevant circulars issued by the SEBI from time to time. Our responsibility is to issue a report on these Financial Statements based on our review.
We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410."Review of Interim Financial Information performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is lirnited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with applicable Accounting Standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 20lS,including the manner in which it is to be disclosed, or that it contains any material misstatement.
For, Sanjay Mehta &Associates Chartered Acco tants FRI[: 011524C
CA Manish Mittal (Partner) M. No. 079452 UDIN : 2507 9 4l}BMIGWZ I 808
SYNCOM FORMULATIONS (TNDIA) LIMITED
Regd Off :- T,Niraj lndustrial Estate,Off Mahakali Caves Road,Andheri (E) Mumbai-400093
Works:- 256-257, Sector - 1, Pithampur, Dist: Dhar-454775
E Mail:- finance@sfil in, Website:- www sfil in, CIN '.- L24239MH1988PLC047759
CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENOED 3OTH JUNE, 2025
| (Rs.ln Lakhs) ( Except EPS) | |||||
|---|---|---|---|---|---|
| S. | Pa rtic u la rs | Quarter Ended | Year Ended | ||
| No. | |||||
| 30t0612025 Unaudited |
31103t2025 *Audited |
30t0612024 Unaudited |
31t03t2025 *Audited |
||
| I | Revenue from Operations | 1 1690 17 | 14887 .64 | 8725 54 | 46501 26 |
| 2 | Other lncome | 603 47 | 694 28 | 133 84 | 1'/ 43 40 |
| 3 | Total lncome(1+2) | 12293.64 | 15581.92 | 8859.38 | 48244.66 |
| 4 | EXPENSES | ||||
| ( a ) Oost of materials consumed | 5961 30 | 8016 05 | 5303 1 3 | 27802 93 | |
| ( b ) t']urchases of Stock-in-I rade | 1568 13 | 1579 28 | 428 61 | 3996 75 | |
| (c ) Changes in inventories of finished goods, Stock-in- Trade and work-in-progress |
(612 48\ | 441 21 | (280 40) | (1066 15) | |
| ( d ) Employee benefits expense | 1595.44 | 1497 .47 | 964.92 | 5217 3-/ | |
| (e)Financecosts | 25 08 | 1168 | 39 03 | 86 49 | |
| ( f ) Depreciation and amortizatron expense | 134 00 | 128 64 | 130 00 | 519 39 | |
| (g)Otherexpenses | 1597 06 | 1578 40 | 1263 88 | 5137 19 | |
| Total expenses(4) | 10268.s3 | 13252.73 | 7849.17 | 41693.97 | |
| 5 | ProfiU(loss) before exceptional items and tax (3- 4) | ||||
| 6 | Exceptional ltems | 2025.11 413 |
2329.19 082 |
1010.21 | 6550.69 |
| 7 | ProfiU(loss) before tax ( 5 - 6 ) | 2029.24 | 2330.01 | 000 | 058 |
| B | Tax expense: | 1010.21 | 6551.27 | ||
| (1 ) Currcnt tax | 432 50 | 460 00 | 243 90 | 1474 43 | |
| (2) Deferred tax | ?.1 30 | 100 58 | 306 | 133 38 | |
| I | Profit (Loss) for the period from continuing operations (7- 8) |
157 5.44 | 1769.43 | 763.25 | 4943.46 |
| 10 | ProfiU(loss) from discontinued operations | 000 | 000 | 000 | 000 |
| 11 | -[ax cxpense of discontinued operations |
000 | 000 | 000 | 000 |
| 1?. | ProfiU(loss) from Discontinued operations (after tax) (10-1 1) | 000 | |||
| 13 | ProfiU(loss) for the period ( 9 + 12 | 1575.44 | 000 1769.43 |
000 763.2s |
000 4943.46 |
| 14 | Other Comprehensive lncome | ||||
| A(i )ltems that will not be reclassified to profit or loss | 000 | 000 | 000 | 000 | |
| (ii ) lncome tax relating to items that will not bc reclassified to | |||||
| profit or loss | 000 | 000 | 000 | 000 | |
| B (i ) ltems that will be reclassifir:d to profit or loss | 403 84 | (228 1e) | 275 93 | 458 02 | |
| (ri ) lncome tax relating to items that will brl reclassified to profit or loss |
000 | 0,00 | 000 | 000 | |
| 15 | Total Comprehensive lncome for the period (Xlll+XlV) | ||||
| (Com prising Prof it (Loss) and Other Com prehensive lncome for the period) |
1979.28 | ||||
| 16 | Pard up Share Capital of the Company ([:acc Valuc 1/.) | 1541.24 | 1039.18 | 5401.48 | |
| 1i | Reservos excludrnq revaluatron rcservcs | 9400 00 000 |
9400 00 | 9400 00 | 9400 00 24815 76 |
| 18 | Earnings per eqrlrty share (for conttnutng operatron) | 000 | |||
| ('l ) l3asrc | 021 | 0 16 | 011 | 0 5t | |
| (2) Diluted | 021 | 016 | 011 | 057 | |
| 19 | Earnings per equity share (for discontinued operation): | ||||
| (1 ) Basic | 000 | 000 | 000 | 000 | |
| (2) Diluted | 000 | 000 | 000 | 000 | |
| ?-0 | Earnings per equity share (for discontinued & continuing operations) |
||||
| (1 ) Basic (2) Diluted |
021 021 |
016 016 |
011 011 |
057 057 |
Place: lndore Date: 08/08/2025 For, Syncom Formulations (lndia) Limited
SYNCOM FORMULATIONS (INDIA) LIMITED
Regd.Off :- 7, Niraj Industrial Estate, Off Mahakali Caves Road, Andheri (E) Mumbai-400093
Works:- 256-257, Sector - 1, Pithampur, Dist: Dhar-454775
E Mail:- [email protected], Website:- www.sfil.in, CIN :- L24239MH1988PLC047759
CONSOLIDATED STATEMENT OF SEGMENT WISE REVENUE, RESULTS ALONG WITH QUARTERLY AND RESULTS FOR THE QUARTER ENDED 30TH JUNE 25
| (Rs.In Lakhs) (Except EPS) | |||||
|---|---|---|---|---|---|
| S. No. | Particulars | Quarter Ended | |||
| 30/06/2025 Unaudited |
31/03/2025 *Audited |
30/06/2024 Unaudited |
31/03/2025 *Audited |
||
| $\mathbf{1}$ | Segment Revenue | ||||
| a) Pharmaceuticals Drugs & Formulations | 12.099.95 | 15,259.54 | 8630.31 | 47,027.33 | |
| b) Trading of Commodities | 104.56 | 213.45 | 132.41 | 825.84 | |
| c) Renting of Property | 89.13 | 108.93 | 96.66 | 391.49 | |
| Total Segment Revenue | 12,293.64 | 15,581.92 | 8859.38 | 48,244.66 | |
| Less: Inter Segment Revenue | 0.00 | ||||
| Revenue from Operations | 12,293.64 | 15,581.92 | 8859.38 | 48,244.66 | |
| 2 | Segment Results Profit(+)/Loss(-) before tax | ||||
| and interest from each segment | |||||
| a) Pharmaceuticals Drugs & Formulations | 1,965.72 | 2,237.06 | 956.25 | 6,258.62 | |
| b) Trading of Commodities | 1.35 | 4.19 | 4.39 | 20.35 | |
| c) Renting of Property | 83.12 | 100.44 | 88.59 | 358.79 | |
| Total Profit before tax | 2,050.19 | 2,341.69 | 1049.23 | 6,637.76 | |
| Less: i) Interest | 25.08 | 11.68 | 39.03 | 86.49 | |
| ii) Other Un-allocable Expenditure | 0.00 | ||||
| Profit before tax | 2,025.11 | 2,330.01 | 1010.20 | 6,551.27 | |
| 3 | (Segment Asset-Segment Liabilities) | ||||
| Segment Asset | |||||
| a) Pharmaceuticals Drugs & Formulations | 39,780.77 | 36,111.42 | 29849.25 | 36,111.42 | |
| b) Trading of Commodities | 259.18 | 448.67 | 964.42 | 448.67 | |
| c) Renting of Property | 4,733.44 | 4,767.98 | 4733.45 | 4,767.98 | |
| Total Segment Asset | 44,773.39 | 41,328.07 | 35547.12 | ||
| Un-allocable Assets | 0.00 | 41,328.07 | |||
| Net Segment Asset | 44,773.39 | 41,328.07 | 35547.12 | 41,328.07 | |
| Segment Liabilities | |||||
| a) Pharmaceuticals Drugs & Formulations | 8,436.63 | 6,888.49 | 5241.86 | 6,888.49 | |
| b) Trading of Commodities | 8.36 | 82.76 | 167.45 | ||
| c) Renting of Property | 133.36 | 141.04 | 181.32 | 82.76 141.04 |
|
| Total Segment Liabilities | 8,578.35 | 7,112.29 | 5590.63 | ||
| Un-allocable Liabilities | 0.00 | 7,112.29 | |||
| Net Segment Liabilities | 8,578.35 | 7,112.29 | |||
| 5590.63 | 7,112.29 |
Notes:-
1 The above results were reviewed by the Audit Committee and approved by the Board at its meeting held on 08/08/2025
2 These above results have been prepared in compliance with the Indian Accounting Standard (referred to as "Ind AS") as notified prescribed under Section 133 of the Companies Act, 2013 read with Companies (Indian Accounting Standards) Rules 2015 as amended from time to time.
3 The company is operating in 3 segments i.e. (a) Pharmaceuticals Drugs & Formulations (b) Trading of Commodities (c) Renting of Property, particulars of segment wise results are given as required.
4 As required under Regulation 33 of SEBI (LODR) Regulations, 2015 the limited review by the Statutory Auditors have been completed for the quarter ended on 30th June, 2025. The report does not have any impact on the above results and notes which needs explanation.
5 Previous period figures have been regrouped/reclassified wherever necessary to confirm to this period classification.
6 The Company currently have 3 (three) Wholly Owned Subsidiaries namely Synmex Pharma Pvt. Ltd., Sante Biotech Pvt. Ltd. And Vincit Biotech International Pvt. Ltd.
Place: Indore Date: 08/08/2025
$\Omega$ $\frac{1}{2}$ Vijay Shankarlal Bankda Managing Director
Din: 00023027
SANJAY MEHTA & ASSOGIATES
Ch artered Accountants
Limited Review Report on Un-audited Consolidated Financial Results for the Quarter and Three Months ended 30m June,2025 pursuant to Regulation 33 of the SEBI (LODR) Regulations,20lS
To, The Board of Directors SYNCOM FORMULATTONS (rNDrA) LTMTTED Indore (M.P.)
- l. We have reviewed the accompanying statement of Consolidated Unaudited Financial Results of SYNCOM FORMULATIONS (II\DIA) LIMITED ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group"), for the period ended June 30,2025 ("the Statement"), attached herewith, being submiffed by the Company pursuant to the requirement of Regulation 33 of the SEBI (LODR) Regulations,2Ol5, as amended including relevant circular issued by the SEBI from time to time.
- This statement which is the responsibility of the Company's Management and has been approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 Interirn Financial Reporting" ("[ND AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other Accounting principles generally accepted in India and in compliance with the Regulation 33 of the SEBI (LODR) Regulations,2Ol5, as amended, including relevant circulars issued by the SEBI from time to time. Our responsibility is to issue a report on these Financial Statements based on our review. 2.
- We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information performed by the Independent Auditor of the Entity", issuedby the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion. n J.
| S. No. | Name of the Company | Relationship with the Holding Company |
||
|---|---|---|---|---|
| 1 | Sante Biotech Pvt. Ltd. | Wholly Owned Subsidiary | ||
| 2. | Synmex Pharma Pvt. Ltd. | Wholly Owned Subsidiary | ||
| 3. | Vincit Biotech International Pvt. Ltd. | Wholly Owned Subsidiary |
- The Statement includes the results of the following entity:
- Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with applicable Accounting Standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 20l5,including the manner in which it is to be disclosed, or that it contains any material misstatement.
For, Sanjay Mehta &Associates Chartered Acc tants FRN: 0ll524c
Place: Indore Date: 8tr August, 2025
(Partner) M. No. 079452 UDIN z 2507 9 452BMIGXA8303